Q4 2025 Management View CEO Lishan Aklog reported that "our EsoGuard test volume in the fourth quarter was 3,664. That exceeds our target range that we've articulated regularly of approximately 2,500 ...
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ...
When clinicians contemplate the use of a new predictive technology in their practice, such as a nomogram, there is always a question of whether the new test is beneficial to their own clinical ...
Sequential, a leader in genomic testing from non-invasive human clinical samples, today announced the successful close of its ...
Under mild Markov assumptions, sufficient conditions for strict minimax optimality of sequential tests for multiple hypotheses under distributional uncertainty are derived. First, the design of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results